Ferring Pharmaceuticals, the privately owned Swiss reproductive-medicine group, has signed an agreement to acquire Gameto in a deal worth up to US$1.3825bn, the companies said on 27 October 2026.
Why Ferring Pharmaceuticals is buying Gameto
The companies said the deal would combine Gameto's reproductive-health innovation with Ferring's expertise and global presence in reproductive medicine, which spans more than 50 years.
“Ferring has been committed to helping people build families for more than 50 years.”
Deal terms and financing
The headline value of up to US$1.3825bn is subject to development, regulatory and commercial milestones. Further financial terms were not disclosed.
Regulatory approvals and timing
Completion remains subject to customary and other closing conditions. Gameto's in vitro maturation programme has not been approved by the US Food and Drug Administration.
Market context
Ferring, founded in 1950 and headquartered in Saint-Prex, Switzerland, markets its medicines in more than 100 countries. Bloomberg reported the transaction as a US$1.4bn deal for the egg-freezing start-up.
